Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRF1 | P14222 | 13/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987025 | 1.00 | PRF1 (0.43) | PRF1GRIA2ALKMCHR1CSNK1D | |
| SCHEMBL29986614 | 0.91 | PRF1 (0.41) | PRF1GRIA2ALKMCHR1CSNK1D | |
| SCHEMBL21903214 | 0.91 | PRF1 (0.41) | PRF1GRIA2ALKMCHR1CSNK1D | |
| SCHEMBL21903267 | 0.88 | PRF1 (0.39) | PRF1GRIA2ALKMCHR1 | |
| SCHEMBL29986095 | 0.88 | PRF1 (0.39) | PRF1GRIA2ALKMCHR1 | |
| SCHEMBL21970987 | 0.85 | TGFBR1 (0.42) | PRF1GRIA2MCHR1CSNK1D | |
| SCHEMBL29986188 | 0.84 | PRF1 (0.40) | PRF1GRIA2ALK | |
| SCHEMBL21903212 | 0.84 | PRF1 (0.40) | PRF1GRIA2ALK | |
| SCHEMBL21903242 | 0.79 | MAP3K5 (0.45) | PRF1GRIA2 | |
| SCHEMBL29986096 | 0.79 | MAP3K5 (0.45) | PRF1GRIA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2020-05-07 | — | — | US | claimed |
| US-11472806-B2 | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | DOMAIN THERAPEUTICS (FR) | 2022-10-18 | — | — | US | disclosed |
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2020-05-07 | — | — | US | disclosed |
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | PRF1 4872/4885GRIA2 23/4885ALK 3045/4885 |
| US-11472806-B2 | Substituted heterocyclic compounds as allosteric modulators of group II metabotropic glutamate receptors | GRM3, GRM1, GRM2 | PRF1 4872/4885GRIA2 23/4885ALK 3045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.